Introduction. Survival rates and treatment algorithms for patients with bladder cancer (BC) depend on the depth of tumor invasion, in particular on the presence of the bladder muscle layer invasion and extraorganic spread. To assess the depth of bladder invasion, the VI-RADS system was developed in 2018, which is based on multiparametric MRI (mpMRI). According to published studies on the VI-RADS effectiveness, there is a high diagnostic accuracy for identifying formations with probable invasion into the muscle layer. The data on BC extraorganic spread are limited and the issue of assessing the sensitivity and specificity of this system requires further study.Aim of the study. To evaluate the diagnostic performance of mpMRI using the VI-RADS system in detecting muscle invasion and BC extraorganic growth.Materials and methods. A prospective study was conducted in the clinics of the National Medical Research Radiological Centre and included 75 patients aged 19 to 85 years, of which 39 (52%) had been newly diagnosed with BC, 36 (48%) had a relapse or continuous tumor growth. All patients underwent pelvic organs mpMRI on a tomograph with a magnetic field induction of 1.5T, followed by transurethral resection (TUR), TUR-biopsy of the bladder or cystectomy no later than 6 weeks after scanning.. The description of the bladder tumor included its measurements, localization and VI-RADS scale assessment. The data obtained by mpMRI were compared with the results of the morphological study using statistical analysis.Results. According to the results of the study, the overall VI-RADS scale sensitivity for categories above 3 (the presence of muscle invasion is equivocal) was 95.15% [90.11%; 99.95%], above 4 (muscle invasion is likely) – 92.59% [82.11%; 97.94%], specificity was determined at the level of 47.62% [25.71%; 70.22%] and 80.95% [58.09%; 94.55%] respectively. When assessing extraorganic spread in 30 patients, the sensitivity was 83.33% [62.62%; 95.26%], specificity – 83.33% [35.88%; 99.58%]. The accuracy and positive predictive value also had high levels from 80 to 95%, in contrast to the negative predictive value (55.56%).Conclusion. The scale for BC invasion depth assessing VI-RADS is characterized by high rates of sensitivity, specificity and accuracy, in particular when used in determining extraorganic spread.
Introduction. Nowdays, CT and/or MRI do not have sufficient specificity for the differential diagnosis of benign renal masses (oncocytoma and angiomyolipoma with minimal fat) from malignant tumors, and therefore all patients undergo surgical treatment.Purpose and objectives. The aim of the study was to evaluate the diagnostic effectiveness of perfusion computed tomography (PCT) for the differential diagnosis of solid renal masses.Materials and methods. The data of 60 patients (61,28±8,46 years) with primary founded solid renal tumors, who underwent PCT at the preoperative stage, were analyzed. Four perfusion indicators, such as BV, BF, PS and MTT, for the renal masses and normal cortex were evaluated.Results. According to the results of the statistical analysis, the perfusion parameters BV, BF, PS of the renal cortex were significantly higher than in tumors of any histological type (p<0,05). A statistically significant difference was found between clear cell, chromophobe and papillary types of renal cell carcinoma in terms of BV and BF (p<0,05), between benign and malignant tumors — in MTT.Conclusions. PCT has great potential in the assessment of neoangiogenesis and differential diagnosis of solid renal masses.
Introduction. Currently, CT and MRI do not reliably differentiate oncocytoma, angiomyolipoma with minimal fat and renal cell carcinoma, and therefore most patients with localized solid renal tumors undergo surgical treatment. Identification of differential signs of benign formations according to imaging methods would make it possible to change the therapeutic tactics in more than a third of cases in patients with newly diagnosed small renal masses (less than 4 cm).Purpose. The aim of the study was to evaluate the diagnostic efficacy of diffusion-weighted MRI (DWI) in the differential diagnosis of solid renal masses.Materials and methods. А prospective study, which included 90 patients aged 34 to 79 years with primary solid renal masses who were examined and treated at the Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation was conducted in the period from February 2019 to October 2021. Before surgery, all patients underwent MRI of the retroperitoneal organs using DWI with b-factors of 0–800 s/mm2 and 0–1000 s/mm2. The diffusion coefficient was quantified on two ADC maps for renal masses of various histological types and the obtained values were compared with each other.Results. According to the results of the statistical analysis, the values of the diffusion coefficient for benign tumors were significantly higher than for RCC (p < 0.05). There was no statistically significant difference between clear cell, chromophobe and papillary types of RCC in terms of diffusion coefficient both at b-factors of 0–800 s/mm2 and at 0–1000 s/mm2.Conclusion. Using DWI we can suggest a benign genesis of a solid renal mass. Differential signs for RCC of various histological types according to diffusion-weighted images were not identified.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.